Lifesci Capital Predicts Immunome FY2024 Earnings
Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital ...
LifeSci Capital Initiates a Buy Rating on Zymeworks (ZYME)
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
What is Lifesci Capital’s Forecast for TARA Q1 Earnings?
Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...
Molecular Partners (MOLN) Initiated with a Buy at LifeSci Capital
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...
Fintel on MSN3d
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation
Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a ...
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...